These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 23388023)

  • 1. Priming with whole-cell versus acellular pertussis vaccine.
    Liko J; Robison SG; Cieslak PR
    N Engl J Med; 2013 Feb; 368(6):581-2. PubMed ID: 23388023
    [No Abstract]   [Full Text] [Related]  

  • 2. Why do pertussis vaccines fail?
    Cherry JD
    Pediatrics; 2012 May; 129(5):968-70. PubMed ID: 22529282
    [No Abstract]   [Full Text] [Related]  

  • 3. Pertussis vaccines for adolescents and adults.
    Cherry JD
    Pediatrics; 2005 Sep; 116(3):755-6. PubMed ID: 16140719
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
    Tapiainen T; Cherry JD; Heininger U
    Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What's wrong with acellular pertussis vaccines?
    Wiedermann BL
    Clin Ther; 2013 Feb; 35(2):115-8. PubMed ID: 23375491
    [No Abstract]   [Full Text] [Related]  

  • 6. Update on adolescent immunization: review of pertussis and the efficacy, safety, and clinical use of vaccines that contain tetanus-diphtheria-acellular pertussis.
    Wilson TR
    J Pediatr Health Care; 2006; 20(4):229-37. PubMed ID: 16831630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age.
    Hendrikx LH; de Rond LG; Oztürk K; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM
    Vaccine; 2011 Aug; 29(34):5725-30. PubMed ID: 21669247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coping with a pertussis outbreak in Alamance County, North Carolina.
    Shapley-Quinn K
    N C Med J; 2013; 74(1):68-9. PubMed ID: 23530389
    [No Abstract]   [Full Text] [Related]  

  • 11. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.
    McIntyre PB; Turnbull FM; Egan AM; Burgess MA; Wolter JM; Schuerman LM
    Vaccine; 2004 Dec; 23(3):380-5. PubMed ID: 15530684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
    Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
    N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
    Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Has the change to acellular pertussis vaccine improved or worsened pertussis control?
    Halperin SA; De Serres G
    CMAJ; 2006 Nov; 175(10):1227. PubMed ID: 17098952
    [No Abstract]   [Full Text] [Related]  

  • 16. Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study.
    Reynolds E; Walker B; Xing D; Southern J; Asokanathan C; Dagg B; Corbel M; Miller E
    Vaccine; 2006 Apr; 24(16):3248-57. PubMed ID: 16480794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing the risk of pertussis in newborn infants.
    Blangiardi F; Ferrera G
    J Prev Med Hyg; 2009 Dec; 50(4):206-16. PubMed ID: 20812515
    [No Abstract]   [Full Text] [Related]  

  • 18. Waning immunity to pertussis following 5 doses of DTaP.
    Tartof SY; Lewis M; Kenyon C; White K; Osborn A; Liko J; Zell E; Martin S; Messonnier NE; Clark TA; Skoff TH
    Pediatrics; 2013 Apr; 131(4):e1047-52. PubMed ID: 23478868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertussis vaccine controversies and acellular pertussis vaccine.
    Shah RC; Shah AR
    Indian J Pediatr; 2003 Jun; 70(6):485-8. PubMed ID: 12921317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pertussis immunisation in adolescents and adults.
    Heininger U
    Adv Exp Med Biol; 2008; 609():72-97. PubMed ID: 18193659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.